Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond
- PMID: 21898045
- DOI: 10.1007/s12017-011-8154-x
Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond
Abstract
Brain-derived neurotrophic factor (BDNF) is the most widely distributed neurotrophin in the central nervous system where it plays several pivotal roles in synaptic plasticity and neuronal survival. As a consequence, BDNF became a key target in the physiopathology of several neurological and psychiatric diseases. Recent studies have reported altered levels of BDNF in the circulation, i.e. serum or plasma, of patients with Alzheimer's disease (AD), and low BDNF levels in the CSF as predictor of future cognitive decline in healthy older subjects. Altered BDNF circulating levels have also been reported in other neurodegenerative and psychiatric disorders, hampering its use as a specific biomarker for AD. Therefore, BDNF seems to be an unspecific biomarker of neuropsychiatric disorders marked by neurodegenerative changes.
Similar articles
-
Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.Biomark Med. 2010 Dec;4(6):871-87. doi: 10.2217/bmm.10.111. Biomark Med. 2010. PMID: 21133708
-
BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.J Psychiatr Res. 2007 Aug;41(5):387-94. doi: 10.1016/j.jpsychires.2006.01.014. Epub 2006 Mar 22. J Psychiatr Res. 2007. PMID: 16554070
-
Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients.Int J Neuropsychopharmacol. 2011 Apr;14(3):399-404. doi: 10.1017/S1461145710001008. Epub 2010 Sep 22. Int J Neuropsychopharmacol. 2011. PMID: 20860877
-
Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.J Alzheimers Dis. 2022;85(3):975-992. doi: 10.3233/JAD-215193. J Alzheimers Dis. 2022. PMID: 34897089 Review.
-
Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer's disease and mild cognitive impairment: results of a meta-analysis.Int J Neurosci. 2020 Mar;130(3):218-230. doi: 10.1080/00207454.2019.1667794. Epub 2019 Sep 24. Int J Neurosci. 2020. PMID: 31518516 Review.
Cited by
-
The demographic and medical correlates of plasma aβ40 and aβ42.Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):244-9. doi: 10.1097/WAD.0b013e318260a8cb. Alzheimer Dis Assoc Disord. 2013. PMID: 22732677 Free PMC article.
-
Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.Rheumatology (Oxford). 2021 Dec 24;61(1):24-41. doi: 10.1093/rheumatology/keab452. Rheumatology (Oxford). 2021. PMID: 34003972 Free PMC article.
-
Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis.J Transl Med. 2022 Mar 14;20(1):126. doi: 10.1186/s12967-022-03312-y. J Transl Med. 2022. PMID: 35287688 Free PMC article.
-
Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition.Sci Rep. 2019 Nov 19;9(1):17069. doi: 10.1038/s41598-019-53604-5. Sci Rep. 2019. PMID: 31745181 Free PMC article.
-
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6. ACS Chem Neurosci. 2014. PMID: 24766396 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials